Table 4.
Results of meta-analysis in the subgroup
| Subgroup | No. of studies (n) | No. of IBD (n)a | OR (95%CI)a | P value for heterogeneity |
|---|---|---|---|---|
| Gender | ||||
| Male | 2 | 21,553 | 2.05 (1.38~3.05) | 0.26 |
| Female | 2 | 15,702 | 1.48 (1.11~1.97) | 0.79 |
| Race | ||||
| Asian | 4 | 19,056 | 1.55 (1.15~2.08) | 0.39 |
| Caucasian | 2 | 22,338 | 1.87 (1.34~2.61) | 0.29 |
| Case type | ||||
| Population | 5 | 329,167 | 1.77 (1.49~2.11) | 0.36 |
| Hospital | 3 | 4848 | 1.50 (0.78~2.88) | 0.18 |
| Control type | ||||
| Normal | 5 | 40,002 | 1.61 (1.28~2.02) | 0.48 |
| Patient | 3 | 292,621 | 1.89 (1.47~2.44) | 0.12 |
| Immunosuppressant | ||||
| Ever use | 2 | 16,894 | 1.43 (1.04~1.96) | 0.31 |
| Never use | 2 | 4078 | 1.47 (0.74~2.92) | 0.07 |
| No. of IBD patients | ||||
| ≥ 10,000 | 3 | 327,190 | 1.79 (1.50~2.14) | 0.42 |
| < 10,000 | 5 | 5433 | 1.39 (0.78~2.48) | 0.19 |
aIBD inflammatory bowel disease, OR odds ratio, CI confidence interval